Clinical Trials Logo

Unstable Angina clinical trials

View clinical trials related to Unstable Angina.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT01947361 Active, not recruiting - Stroke Clinical Trials

Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber)

Start date: January 2012
Phase: N/A
Study type: Observational

Study of heterogeneity in associations between heart rate and the initial presentation of 12 cardiovascular diseases.

NCT ID: NCT01937065 Active, not recruiting - Stroke Clinical Trials

Social Deprivation and Initial Presentation of 12 Cardiovascular Diseases: a CALIBER Study

IP4
Start date: January 2012
Phase: N/A
Study type: Observational

Study of heterogeneity in associations between social deprivation and the initial presentation of 12 cardiovascular diseases.

NCT ID: NCT01864031 Active, not recruiting - Heart Failure Clinical Trials

The Role of Alcohol Consumption in the Aetiology of Different Cardiovascular Disease Phenotypes: a CALIBER Study

Start date: January 1997
Phase: N/A
Study type: Observational

The association between alcohol consumption and cardiovascular disease (CVD) has mostly been examined using broad endpoints or cause-specific mortality. The purpose of our study is to compare the effect of alcohol consumption in the aetiology of a range of cardiovascular disease phenotypes.

NCT ID: NCT01687686 Active, not recruiting - Unstable Angina Clinical Trials

Differential Effects of Lipids on Cardiovascular Diseases: A CALIBER Study

Start date: January 2001
Phase: N/A
Study type: Observational

The role of lipids as risk factors for cardiovascular events is well-documented, although events studied have largely been broad classes without specific detail. This study will examine a more refined set of endpoints.

NCT ID: NCT00066898 Active, not recruiting - Clinical trials for Coronary Artery Disease

ARISE – Aggressive Reduction of Inflammation Stops Events

Start date: June 2003
Phase: Phase 3
Study type: Interventional

To assess the safety and efficacy of AGI-1067, as compared to placebo, in the treatment of vascular inflammation and atherosclerosis by assessing the reduction in cardiovascular events.